Christiana Anastasiadou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christiana Anastasiadou has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Anastasios Papapetrou
Department of Vascular Surgery - General Hospital of Attica "KAT"
6 shared publicationsAngelos Megalopoulos
Vascular Surgery Department, General Hospital of Thessaloniki "George Papanikolaou", Thessaloniki, GRC
5 shared publications- George Galyfos
National and Kapodistrian University of Athens
5 shared publications Chrisostomos Maltezos
Department of Vascular Surgery, KAT General Hospital, Athens, Greece
4 shared publicationsGeorge Trellopoulos
Department of Vascular Surgery - General Hospital of Thessaloniki "Georgios Papanikolaou"
3 shared publications- Anastasios Papapetrou
Department of Vascular Surgery, “KAT” General Hospital of Athens, 14561 Kifisia, Greece
2 shared publications
Latest Publications
- Open Access
Mid- to Long-Term Outcomes of Endovascular Aneurysm Repair Using the Ankura Stent Graft: An Eight-Year Single-Center Experience
Background and Objectives: The Ankura stent graft was introduced in Europe in 2015 for the endovascular repair of infrarenal abdominal aortic aneurysms (AAAs). Evidence regarding its long-term efficacy remains limited. This study presents eight years of clinical experience with the Ankura endograft for endovascular aneurysm repair (EVAR) at a tertiary university vascular center. Materials and Methods: This single-center retrospective study included patients who underwent elective EVAR with the Ankura endograft between January 2015 and January 2023. All patients were anatomically suitable according to the instructions for use (IFU). Computed tomography angiography was performed at 1 and 12 months and annually thereafter during follow-up; the surveillance protocol was subsequently modified to use duplex ultrasound. Primary outcomes were categorized as early (technical success, clinical success, and 30-day mortality and morbidity) or late (aneurysm-related and non-aneurysm-related mortality). Results: A total of 220 patients were included (211 men [95.9%]); the mean age was 71.41 years (range, 49–87 years); and the mean aneurysm diameter was 59.15 mm (range, 32–109 mm). Primary and secondary technical success rates were 97.3% and 100%, respectively, and the clinical success rate was 96.8%. Thirty-day morbidity and mortality rates were 6.3% and 0%, respectively. No perioperative conversions occurred. The mean follow-up duration was 51.76 months (range, 1–131 months). Freedom from reintervention at 24, 36, 48, and 72 months was 98.2%, 97.7%, 97.2%, and 95.9%, respectively. Iliac limb patency was 99.5%. Aneurysm-related and non-aneurysm-related mortality during follow-up were 2.2% and 20.45%, respectively. Conclusions: In this study, the Ankura AAA stent graft demonstrated durable efficacy, with a high iliac limb patency rate, a low reintervention rate, and low aneurysm-related mortality during follow-up. Its long-term efficacy and safety should be evaluated in larger studies.
Open AccessMid- to Long-Term Outcomes of Endovascular Aneurysm Repair Using the Ankura Stent Graft: An Eight-Year Single-Center Experience
Background and Objectives: The Ankura stent graft was introduced in Europe in 2015 for the endovascular repair of infrarenal abdominal aortic aneurysms (AAAs). Evidence regarding its long-term efficacy remains limited. This study presents eight years of clinical experience with the Ankura endograft for endovascular aneurysm repair (EVAR) at a tertiary university vascular center. Materials and Methods: This single-center retrospective study included patients who underwent elective EVAR with the Ankura endograft between January 2015 and January 2023. All patients were anatomically suitable according to the instructions for use (IFU). Computed tomography angiography was performed at 1 and 12 months and annually thereafter during follow-up; the surveillance protocol was subsequently modified to use duplex ultrasound. Primary outcomes were categorized as early (technical success, clinical success, and 30-day mortality and morbidity) or late (aneurysm-related and non-aneurysm-related mortality). Results: A total of 220 patients were included (211 men [95.9%]); the mean age was 71.41 years (range, 49–87 years); and the mean aneurysm diameter was 59.15 mm (range, 32–109 mm). Primary and secondary technical success rates were 97.3% and 100%, respectively, and the clinical success rate was 96.8%. Thirty-day morbidity and mortality rates were 6.3% and 0%, respectively. No perioperative conversions occurred. The mean follow-up duration was 51.76 months (range, 1–131 months). Freedom from reintervention at 24, 36, 48, and 72 months was 98.2%, 97.7%, 97.2%, and 95.9%, respectively. Iliac limb patency was 99.5%. Aneurysm-related and non-aneurysm-related mortality during follow-up were 2.2% and 20.45%, respectively. Conclusions: In this study, the Ankura AAA stent graft demonstrated durable efficacy, with a high iliac limb patency rate, a low reintervention rate, and low aneurysm-related mortality during follow-up. Its long-term efficacy and safety should be evaluated in larger studies.
- Open Access
- 11 August 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (8) , 126
Effect of Cilostazol in the Expression of Biomarkers and Neurological Outcome Following Experimentally Induced Cerebrovascular Accident—Experimental Protocol
Objective: Several strategies have been described for stroke prevention, and the most commonly used medication is aspirin. Cilostazol, which is a substance with a pleiotropic effect, is still not well investigated. In this study, we aimed to delineate the effects of mono- and combinatorial pre-treatment upon neurological status and biomarkers, namely protein S100b, GFAP, procalcitonin, and galectin-3, following stroke. Methods: Twelve-week-old Sprague–Dawley rats were randomly assigned to four groups, each containing six rats: control group (normal saline), cilostazol group (30 mg/kg/daily), aspirin group (10 mg/kg/daily), and aspirin/cilostazol group. Each substance was administered by gavage for four weeks. All animals were subjected to cerebral ischemia for 2 h using intraluminal middle cerebral artery occlusion. A neurological examination was performed, serum concentrations of biomarkers were determined, and the animals were then sacrificed. Results: All treatment groups exhibited variations in the severity of immediate neurological presentation. Unlike the control group, where all rats presented with severe focal neurology or mortality, most rats in the treatment groups displayed no to moderate focal neurology. Moreover, the aspirin/cilostazol group consistently exhibited significantly lower levels in the studied biomarkers compared to other groups. Conclusions: Co-administration of cilostazol and aspirin significantly ameliorates the immediate expression of the studied biomarkers. Further large-scale studies are needed to investigate the effect of combined therapy for primary and secondary prevention of stroke, using not only serum biomarkers but other specific clinical and laboratory endpoints.
- 11 August 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (8) , 126
Open AccessEffect of Cilostazol in the Expression of Biomarkers and Neurological Outcome Following Experimentally Induced Cerebrovascular Accident—Experimental Protocol
Objective: Several strategies have been described for stroke prevention, and the most commonly used medication is aspirin. Cilostazol, which is a substance with a pleiotropic effect, is still not well investigated. In this study, we aimed to delineate the effects of mono- and combinatorial pre-treatment upon neurological status and biomarkers, namely protein S100b, GFAP, procalcitonin, and galectin-3, following stroke. Methods: Twelve-week-old Sprague–Dawley rats were randomly assigned to four groups, each containing six rats: control group (normal saline), cilostazol group (30 mg/kg/daily), aspirin group (10 mg/kg/daily), and aspirin/cilostazol group. Each substance was administered by gavage for four weeks. All animals were subjected to cerebral ischemia for 2 h using intraluminal middle cerebral artery occlusion. A neurological examination was performed, serum concentrations of biomarkers were determined, and the animals were then sacrificed. Results: All treatment groups exhibited variations in the severity of immediate neurological presentation. Unlike the control group, where all rats presented with severe focal neurology or mortality, most rats in the treatment groups displayed no to moderate focal neurology. Moreover, the aspirin/cilostazol group consistently exhibited significantly lower levels in the studied biomarkers compared to other groups. Conclusions: Co-administration of cilostazol and aspirin significantly ameliorates the immediate expression of the studied biomarkers. Further large-scale studies are needed to investigate the effect of combined therapy for primary and secondary prevention of stroke, using not only serum biomarkers but other specific clinical and laboratory endpoints.
- Open Access
- 28 April 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (5) , 69
Effect of Cilostazol and Aspirin During Hyperacute Stroke Phase in Rats: An Experimental Research Study
Objective: The contralateral hippocampus, a critical region for cognitive function, is often overlooked in everyday clinical practice and stroke research. This study aimed to evaluate the effect of specific antiplatelet agents on the hippocampus (ipsilateral and contralateral) during the hyperacute phase of stroke. Materials and Methods: Twelve-week-old rats were randomly assigned to four groups, each containing six rats: a cilostazol group, an aspirin group, an aspirin plus cilostazol group, and a control group. Each substance was administered for four weeks. Permanent brain ischemia was induced over 2 h using intraluminal middle cerebral artery occlusion. A neurologic examination was conducted, followed by euthanasia and histological examination of the CA1 hippocampal region. The hematoxylin and eosin stain was used to assess the total number of intact neuronal cell bodies and pyknotic nuclei, an indicator of early irreversible neuronal injury. Results: In the ipsilateral hippocampus, monotherapy with either aspirin or cilostazol significantly reduced pyknotic nuclei compared with the control group (p = 0.0016 and p = 0.0165, respectively). However, combination therapy showed no significant difference from the controls (p = 0.2375). In the contralateral hippocampus, cilostazol monotherapy demonstrated significantly reduced pyknotic nuclei (p = 0.0098), whereas aspirin monotherapy and combination therapy did not (p = 0.1009 and p = 0.9999, respectively). A cumulative analysis of both hemispheres revealed that monotherapy with aspirin or cilostazol markedly reduced injury markers (p = 0.0002 and p = 0.0001, respectively), whereas combined therapy revealed no significant benefit (p = 0.1984). A neurological assessment indicated that the most severe deficits were in the combination therapy group. Conclusions: To the best of our knowledge, this is the first study to compare acute histopathological changes in the affected and unaffected hippocampus after a stroke in a rat model. Dual antiplatelet therapy resulted in worse outcomes (histopathological and neurological) than monotherapy.
- 28 April 2025
- Published by MDPI AG in Neurology International
- Vol. 17 (5) , 69
Open AccessEffect of Cilostazol and Aspirin During Hyperacute Stroke Phase in Rats: An Experimental Research Study
Objective: The contralateral hippocampus, a critical region for cognitive function, is often overlooked in everyday clinical practice and stroke research. This study aimed to evaluate the effect of specific antiplatelet agents on the hippocampus (ipsilateral and contralateral) during the hyperacute phase of stroke. Materials and Methods: Twelve-week-old rats were randomly assigned to four groups, each containing six rats: a cilostazol group, an aspirin group, an aspirin plus cilostazol group, and a control group. Each substance was administered for four weeks. Permanent brain ischemia was induced over 2 h using intraluminal middle cerebral artery occlusion. A neurologic examination was conducted, followed by euthanasia and histological examination of the CA1 hippocampal region. The hematoxylin and eosin stain was used to assess the total number of intact neuronal cell bodies and pyknotic nuclei, an indicator of early irreversible neuronal injury. Results: In the ipsilateral hippocampus, monotherapy with either aspirin or cilostazol significantly reduced pyknotic nuclei compared with the control group (p = 0.0016 and p = 0.0165, respectively). However, combination therapy showed no significant difference from the controls (p = 0.2375). In the contralateral hippocampus, cilostazol monotherapy demonstrated significantly reduced pyknotic nuclei (p = 0.0098), whereas aspirin monotherapy and combination therapy did not (p = 0.1009 and p = 0.9999, respectively). A cumulative analysis of both hemispheres revealed that monotherapy with aspirin or cilostazol markedly reduced injury markers (p = 0.0002 and p = 0.0001, respectively), whereas combined therapy revealed no significant benefit (p = 0.1984). A neurological assessment indicated that the most severe deficits were in the combination therapy group. Conclusions: To the best of our knowledge, this is the first study to compare acute histopathological changes in the affected and unaffected hippocampus after a stroke in a rat model. Dual antiplatelet therapy resulted in worse outcomes (histopathological and neurological) than monotherapy.
- Open Access
- 23 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77862
Resolving the Challenges of an Enormous Popliteal Artery Aneurysm Rupture
Popliteal artery aneurysm rupture represents a diagnostic and therapeutic challenge. In this case report, we report the open surgical therapy of an enormous ruptured popliteal artery aneurysm (rPAA) (13 cm), emphasizing key points in diagnosis and treatment decision-making. The symptomatology of rPAAs is often misleading, with nonspecific signs such as edema and pain, which can lead to delayed diagnosis. Early recognition and appropriate treatment are critical to avoid complications such as acute limb ischemia and amputation.
- 23 January 2025
- Published by Springer Nature in Cureus
- Vol. 17 (1) , e77862
Open AccessResolving the Challenges of an Enormous Popliteal Artery Aneurysm Rupture
Popliteal artery aneurysm rupture represents a diagnostic and therapeutic challenge. In this case report, we report the open surgical therapy of an enormous ruptured popliteal artery aneurysm (rPAA) (13 cm), emphasizing key points in diagnosis and treatment decision-making. The symptomatology of rPAAs is often misleading, with nonspecific signs such as edema and pain, which can lead to delayed diagnosis. Early recognition and appropriate treatment are critical to avoid complications such as acute limb ischemia and amputation.
- Open Access
- 16 December 2024
- Published by The Korean Society for Vascular Surgery in Vascular Specialist International
- Vol. 40, 39
Duplex Ultrasound of the Femoral Vein for Monitoring Endovascular Treatment of Aortocaval Fistula: A Case Report
Aortocaval fistulas, typically linked to aortoiliac aneurysms, are rare vascular conditions. Currently, endovascular therapy is preferred treatment approach. However, endovascular therapy requires frequent and extended follow-up evaluations. Herein, we emphasize a noteworthy clinical finding in this disease: the presence of a pulsatile femoral vein. Additionally, we propose a novel, simple, and easily performed radiation-free method for postoperative assessment of fistula presence or resolution: duplex ultrasound of the femoral vein. While duplex ultrasound cannot substitute other diagnostic modalities, this technique offers a quick, cost-effective, and repeatable adjunct for monitoring.
- 16 December 2024
- Published by The Korean Society for Vascular Surgery in Vascular Specialist International
- Vol. 40, 39
Open AccessDuplex Ultrasound of the Femoral Vein for Monitoring Endovascular Treatment of Aortocaval Fistula: A Case Report
Aortocaval fistulas, typically linked to aortoiliac aneurysms, are rare vascular conditions. Currently, endovascular therapy is preferred treatment approach. However, endovascular therapy requires frequent and extended follow-up evaluations. Herein, we emphasize a noteworthy clinical finding in this disease: the presence of a pulsatile femoral vein. Additionally, we propose a novel, simple, and easily performed radiation-free method for postoperative assessment of fistula presence or resolution: duplex ultrasound of the femoral vein. While duplex ultrasound cannot substitute other diagnostic modalities, this technique offers a quick, cost-effective, and repeatable adjunct for monitoring.
- 19 November 2024
- Published by Elsevier in Journal of Vascular Surgery
WITHDRAWN: A systematic review of therapies for aortobronchial fistulae
- 19 November 2024
- Published by Elsevier in Journal of Vascular Surgery
WITHDRAWN: A systematic review of therapies for aortobronchial fistulae
- 1 February 2022
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 75 (2) , 753-761.e3
A systematic review of therapies for aortobronchial fistulae
- 1 February 2022
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 75 (2) , 753-761.e3
A systematic review of therapies for aortobronchial fistulae
- 1 February 2020
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 63, 399-408
Fenestrated Endovascular Repair for Pararenal or Juxtarenal Abdominal Aortic Aneurysms: a Systematic Review
- 1 February 2020
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 63, 399-408
Fenestrated Endovascular Repair for Pararenal or Juxtarenal Abdominal Aortic Aneurysms: a Systematic Review
- Open Access
- 31 December 2019
- Published by The Korean Society for Vascular Surgery in Vascular Specialist International
- Vol. 35 (4) , 237-240
Total Endovascular Therapy of Abdominal Aortic Aneurysm, Peripheral Artery Disease, and Chronic Mesenteric Ischemia: A Challenging Case
We presented a challenging case of a patient diagnosed with abdominal aortic aneurysm (AAA), peripheral artery disease, and chronic mesenteric ischemia (CMI). Herein, we describe the treatment in this high-risk patient diagnosed with CMI who also had critical limb ischemia and his AAA had rapidly expanded. First we performed angioplasty and celiac arterial stenting. Afterwards, we proceeded to perform balloon angioplasty of the iliac arteries and chimney endovascular aneurysm repair (Ch-EVAR) preserving the inferior mesenteric artery (IMA). The patient was discharged three days later and his IMA remained patent eighteen months post-operation. A thorough pre-operative assessment is essential in such challenging cases. Minimally invasive procedures like endovascular therapy and the chimney technique extend the prognoses in high-risk patients.
- 31 December 2019
- Published by The Korean Society for Vascular Surgery in Vascular Specialist International
- Vol. 35 (4) , 237-240
Open AccessTotal Endovascular Therapy of Abdominal Aortic Aneurysm, Peripheral Artery Disease, and Chronic Mesenteric Ischemia: A Challenging Case
We presented a challenging case of a patient diagnosed with abdominal aortic aneurysm (AAA), peripheral artery disease, and chronic mesenteric ischemia (CMI). Herein, we describe the treatment in this high-risk patient diagnosed with CMI who also had critical limb ischemia and his AAA had rapidly expanded. First we performed angioplasty and celiac arterial stenting. Afterwards, we proceeded to perform balloon angioplasty of the iliac arteries and chimney endovascular aneurysm repair (Ch-EVAR) preserving the inferior mesenteric artery (IMA). The patient was discharged three days later and his IMA remained patent eighteen months post-operation. A thorough pre-operative assessment is essential in such challenging cases. Minimally invasive procedures like endovascular therapy and the chimney technique extend the prognoses in high-risk patients.
- 7 November 2019
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 65, 285.e7-285.e9
Early Post-EVAR Rupture in a Patient with Early Type II Endoleak: A Borderline Treatment
- 7 November 2019
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 65, 285.e7-285.e9
Early Post-EVAR Rupture in a Patient with Early Type II Endoleak: A Borderline Treatment